Top-News
Werbung
Attraktive Knock-Outs auf Abbott Laboratories Inc
Typ Hebel Bid / Ask WKN
Call
4,6 4,72 € / 4,74 €
SW1X4G
Typ Hebel Bid / Ask WKN
Put
4,9 2,21 € / 2,22 €
SW1F41
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Abbott Laboratories Inc

Abbott Laboratories Aktie News

Aktie
WKN:  850103 ISIN:  US0028241000 US-Symbol:  ABT Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  USA
125,39 $
-0,01 $
-0,01%
107,71 € 20:57:35 Uhr
Depot/Watchlist
Marktkapitalisierung *
194,40 Mrd. €
Streubesitz
19,42%
KGV
14,73
Dividende
0,59 $
Dividendenrendite
0,47%
neu: Nachhaltigkeits-Score
42 %
Index-Zuordnung
S&P 500
Weiter abwärts? Short handeln - Jetzt mit Hebel 6,51: VG4D76
Werbung

Abbott Laboratories News

31.07.25 - dpa-AFX
AKTIEN IM FOKUS: Pharma unter Druck - Trump will günstigere Preisen
Die Aussicht auf politischen Druck auf die Medikamentenpreise in den USA hat am Donnerstag die Branche belastet. Bristol Myers Squibb fielen um 5 Prozent, Eli Lilly um 3 Prozent ...
18.07.25 - wallstreetONLINE Redaktion
Nach schwachen Zahlen: Beliebter Dividendenwachstumswert stürzt ab: Jetzt zugreifen?
Für die Anteile von Abbott Laboratories ging es am Donnerstag nach schwachen Zahlen um 8,5 Prozent bergab. Sollten Anlegerinnen und Anleger jetzt einsteigen? Seit 36 Jahren ...
17.07.25 - PR Newswire
Abbott Reports Second-Quarter 2025 Results
Abbott Reports Second-​Quarter 2025 Results PR Newswire
15.07.25 - PR Newswire
Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity
Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-​Billion Dollar Revenue Opportunity PR Newswire
15.07.25 - PR Newswire
Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity
Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-​Billion Dollar Revenue Opportunity PR Newswire
26.06.25 - PR Newswire
Abbott Hosts Conference Call for Second-Quarter Earnings
Abbott Hosts Conference Call for Second-​Quarter Earnings PR Newswire
20.06.25 - PR Newswire
New Research on Abbott's Healthy Food Rx Program Shows 'Food is Medicine' Approach Helps People Living With Diabetes Eat Better and Feel Healthier
New Research on Abbott's Healthy Food Rx Program Shows 'Food is Medicine' Approach Helps People Living With Diabetes Eat Better and Feel Healthier PR Newswire
13.06.25 - PR Newswire
Abbott Declares 406th Consecutive Quarterly Dividend
Abbott Declares 406th Consecutive Quarterly Dividend PR Newswire
27.05.25 - PR Newswire
Abbott Receives FDA Approval for Tendyne™, First-of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery
Abbott Receives FDA Approval for Tendyne™, First-​of-Its-Kind Device to Replace the Mitral Valve Without Open-​Heart Surgery PR Newswire
15.05.25 - PR Newswire
Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes
Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes PR Newswire
07.05.25 - PR Newswire
Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent
Abbott and Real Madrid Kick Off Search to Empower Young Soccer Talent PR Newswire
01.05.25 - PR Newswire
MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races
MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races PR Newswire
29.04.25 - PR Newswire
Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information
Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information PR Newswire
29.04.25 - PR Newswire
CIBC introduces additional U.S. Canadian Depositary Receipts ("CDRs")
CIBC introduces additional U.S. Canadian Depositary Receipts ("CDRs") Canada NewsWire
27.04.25 - PR Newswire
Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology
Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology PR Newswire
26.04.25 - PR Newswire
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib PR Newswire
26.04.25 - PR Newswire
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib PR Newswire
25.04.25 - wallstreetONLINE Redaktion
Ihre wichtigsten Termine: Heute im Fokus: Bayer, Continental, Steel Dynamics, AbbVie und Schlumberger
Gut geplant in den Tag. Mit dem wO-​Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine ...
16.04.25 - PR Newswire
Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance
Abbott Reports First-​Quarter 2025 Results and Reaffirms Full-Year Guidance PR Newswire
16.04.25 - wallstreetONLINE Redaktion
Ihre wichtigsten Termine: Spannende Updates von: Nestle, Abbott Laboratories, Heineken & Lindt & Sprüngli
Gut geplant in den Tag. Mit dem wO-​Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine ...

Newssuche

Videos

newspaper
10:20 Uhr +0,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »